Keith R. McCrae

Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice.

Impaired fibrinolysis in the antiphospholipid syndrome.

Blind men and the APS.

Thrombocytopenia in pregnancy.

Sutton's law and anti-β₂GPI antibodies.

Endothelial cell activation by antiphospholipid antibodies is modulated by Kruppel-like transcription factors.

Immune thrombocytopenia: no longer 'idiopathic'.

RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME).

Restoration of glycemic control in patients with type 2 diabetes mellitus after bariatric surgery is associated with reduction in microparticles.

A novel pathway for human endothelial cell activation by antiphospholipid/anti-β2 glycoprotein I antibodies.

Chimeric glutathione S-transferases containing inserts of kininogen peptides: potential novel protein therapeutics.

Kininogen deficiency protects from ischemic neurodegeneration in mice by reducing thrombosis, blood-brain barrier damage, and inflammation.

Antigen and substrate withdrawal in the management of autoimmune thrombotic disorders.

Management and outcomes for patients with TTP: analysis of 100 cases at a single institution.

Immune thrombocytopenia.

Anti-β2GPI antibodies stimulate endothelial cell microparticle release via a nonmuscle myosin II motor protein-dependent pathway.

The least of 3 evils: exposure to red blood cell transfusion, anemia, or both?

Better late than never?

Risk stratification strategies for cancer-associated thrombosis: an update.

Rituximab for treatment of inhibitors in haemophilia A. A Phase II study.

Recent advances in the antiphospholipid antibody syndrome.

Antiplatelet antibodies in oxaliplatin-induced immune thrombocytopenia.

Symptomatic and incidental venous thromboembolic disease are both associated with mortality in patients with prostate cancer.

Circulating microparticles in patients with antiphospholipid antibodies: characterization and associations.

Lipocalin-2 released in response to cerebral ischaemia mediates reperfusion injury in mice.

Increased morbidity during long-term follow-up of survivors of thrombotic thrombocytopenic purpura.

The antiphospholipid syndrome: still an enigma.

Recurrent venous thromboembolism in glioblastoma.

FcγRIII in ITP: it ain't over 'til it's over.

Predictors of recurrent venous thromboembolism and bleeding on anticoagulation.

Treatment of chronic immune thrombocytopenia in children with romiplostim.

Novel role for p56/Lck in regulation of endothelial cell survival and angiogenesis.

Evaluation of US prescription patterns: Are treatment guidelines for cancer-associated venous thromboembolism being followed?

Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group.

Blind men and the refractory ITP elephant.

Centralizing care of cancer-associated thromboembolism: The Cleveland Clinic experience.

In vitro characterization of SynthoPlate™ (synthetic platelet) technology and its in vivo evaluation in severely thrombocytopenic mice.

Post-traumatic stress disorder and depression in survivors of thrombotic thrombocytopenic purpura.

Predicting risk of venous thromboembolism in hospitalized cancer patients: Utility of a risk assessment tool.

Depression and post-traumatic stress disorder in individuals with hereditary hemorrhagic telangiectasia: A cross-sectional survey.

Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia.

Extracellular Vesicles in the Antiphospholipid Syndrome.

Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.

Diagnosis and management of the antiphospholipid syndrome.

CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors.

Limited role of kininogen in the host response during gram-negative pneumonia-derived sepsis.

Preoperative Anemia in Cardiac Operation: Does Hemoglobin Tell the Whole Story?

Splenectomy for immune thrombocytopenia: down but not out.

Novel Mechanism of Cancer Thrombosis Induced by Microvesicles.

Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis.

Effects of anti-β2GPI antibodies on VWF release from human umbilical vein endothelial cells and ADAMTS13 activity.

Factor XII Activation Promotes Platelet Consumption in the Presence of Bacterial-Type Long-Chain Polyphosphate In Vitro and In Vivo.

Kininogen deficiency or depletion reduces enhanced pause independent of pulmonary inflammation in a house dust mite-induced murine asthma model.

Duration of anticoagulant therapy and VTE recurrence in patients with cancer.

Plasma kallikrein structure reveals apple domain disc rotated conformation compared to factor XI.

Complement in the Pathophysiology of the Antiphospholipid Syndrome.

Bleeding incidence and risk factors among cancer patients treated with anticoagulation.

Implementation of an electronic medical record tool for early detection of deep vein thrombosis in the ambulatory oncology setting.

Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants.

A non-circulating pool of factor XI associated with glycosaminoglycans in mice.

Prognostic Value of Preoperative Red Cell Distribution Width: Fine-Tuning by Mean Corpuscular Volume.

American Society of Hematology 2019 guidelines for immune thrombocytopenia.

Clinical outcomes of isolated distal deep vein thrombosis versus proximal venous thromboembolism in cancer patients: The Cleveland Clinic experience.

Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS.

Healthcare resource utilization and costs associated with venous thromboembolism recurrence in patients with cancer.

Editorial: Proceedings of KININ2018CLE, Cleveland, Ohio, June 18-20, 2018: A Compendium of the Presentations.

Outcomes of Cardiovascular Surgery Utilizing Heparin versus Direct Thrombin Inhibitors in Cardiopulmonary Bypass in Patients with Previously Diagnosed HIT.

RNA expression and risk of venous thromboembolism in lung cancer.

"HIT"ing back against NETs.

FcRn augments induction of tissue factor activity by IgG-containing immune complexes.

Report of a 'consensus' on the lines of therapy for primary immune thrombocytopenia in adults, promoted by the Italian Gruppo di Studio delle Piastrine.

The J-elongated conformation of β-glycoprotein I predominates in solution: implications for our understanding of antiphospholipid syndrome.

Factor XII and kininogen asymmetric assembly with gC1qR/C1QBP/P32 is governed by allostery.

Mechanisms and biomarkers of cancer-associated thrombosis.

SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy.

Risk of thromboembolism in patients with ALK- and EGFR-mutant lung cancer: A cohort study.

SARS-CoV-2 Receptors are Expressed on Human Platelets and the Effect of Aspirin on Clinical Outcomes in COVID-19 Patients.

Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.

Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method.

Plasmin-mediated cleavage of high-molecular-weight kininogen contributes to acetaminophen-induced acute liver failure.

A novel "vascular" thrombophilia.

Efficacy and Safety of Avatrombopag in Patients with Chronic Immune Thrombocytopenia: A Systematic Literature Review and Network Meta-Analysis.

Thrombotic thrombocytopenia due to SARS-CoV-2 vaccination.

Effect of aspirin on short-term outcomes in hospitalized patients with COVID-19.

Increased Incidence of Venous Thromboembolism with Cancer Immunotherapy.

Stress Granule-Mediated Oxidized RNA Decay in P-Body: Hypothetical Role of ADAR1, Tudor-SN, and STAU1.

Sclerotherapy Versus Cautery/Laser Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia.

Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia.

Polyphosphate expression by cancer cell extracellular vesicles mediates binding of factor XII and contact activation.

Biomarker signatures in cancer patients with and without venous thromboembolism events: a substudy of CASSINI.

Eculizumab for refractory thrombosis in antiphospholipid syndrome.

Race, rituximab, and relapse in TTP.

Development and performance of a hereditary hemorrhagic telangiectasia-specific quality-of-life instrument.

Old is new again: emergence of thromboembolic complications in cancer patients on immunotherapy.

Emerging Therapies in Antiphospholipid Syndrome.

Anti-HK antibody inhibits the plasma contact system by blocking prekallikrein and factor XI activation in vivo.

C1 inhibitor deficiency enhances contact pathway-mediated activation of coagulation and venous thrombosis.

Transcriptome analysis suggests a central role for complement and C5aR1 in neutrophil activation in APS.

Factor XII promotes the thromboinflammatory response in a rat model of venoarterial extracorporeal membrane oxygenation.

High molecular weight kininogen interactions with the homologs prekallikrein and factor XI: importance to surface-induced coagulation.

How to diagnose and manage antiphospholipid syndrome.

A descriptive analysis of fatal outcomes in immune thrombotic thrombocytopenic purpura in the USTMA TTP Registry.

Dysregulated platelet function in patients with postacute sequelae of COVID-19.

The 2022 review of the 2019 American Society of Hematology guidelines on immune thrombocytopenia.

A machine learning approach to predict mortality due to immune-mediated thrombotic thrombocytopenic purpura.

A "backup plan" for ADAMTS13 deficiency in TTP.

Catastrophic antiphospholipid syndrome: challenging case and importance of multidisciplinary evaluation and management.

Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia.

Complement biosensors identify a classical pathway stimulus in complement-mediated thrombotic microangiopathy.

Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era.

Pomalidomide in Hereditary Hemorrhagic Telangiectasia. Reply.

Protection of β2GPI-deficient mice from thrombosis reflects a defect in PAR3-facilitated platelet activation.

Idiopathic multicentric Castleman disease - TAFRO results in high levels of mTOR activator SVEP1, tissue factor, and endotheliopathy.

Genetic and Epigenetic Dysregulation of CR1 is Associated with Catastrophic Antiphospholipid Syndrome (CAPS).